

Market Announcement

17 June 2024

Enlitic, Inc. (ASX: ENL) – Trading Halt

Description

The securities of Enlitic, Inc. ('ENL') will be placed in trading halt at the request of ENL, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Wednesday, 19 June 2024 or when the announcement is released to the market.

Issued by

ASX Compliance

17 June 2024

Request for Trading Halt

Enlitic, Inc. (ASX: ENL) (“the Company”) requests an immediate trading halt be placed on its securities in accordance with Listing Rule 17.1.

Set out below is the information required by ASX Listing Rule 17.1:

1. The reason for the trading halt is that the Company anticipates making a material announcement in relation to new partnerships.
2. The trading halt is requested from the date of this letter until the commencement of trade on Wednesday 19 June 2024, or such earlier time as the Company makes an announcement to update the market.
3. The Company is not aware of any reason why the trading halt should not be granted.

– ENDS –

This announcement was authorised for release by the Company Secretary.

Enquiries:

Enlitic Investor Relations

Australia:
invest_au@enlitic.com

USA:
invest@enlitic.com

About Enlitic

Enlitic is a software company that uses artificial intelligence to develop software products that manage medical imaging data in radiology (such as MRI, CT scans, X-ray and ultrasound images) and licences such products to healthcare providers. Enlitic’s products (including its current product offering and product suite under development) seek to standardise, protect, integrate, and analyse data to create the foundation of a real-world evidence platform that has the ability to improve clinical workflows, increase efficiencies, and expand capacity. Read more at enlitic.com.